Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Cervarix

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Vaccin mot papillomvirus (humant, typ 16 och 18) Testmiljö

Vaccin mot papillomvirus (humant, typ 16 och 18)

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.

  4. Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].

  5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.

  6. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.

  7. Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.

  8. Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.

  9. Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.

  10. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
  4. Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].
  5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.
  6. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.
  7. Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
  8. Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.
  9. Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.
  10. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017